Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756222 · ClinicalTrials.gov registry record
Bicuspid Aortic Valve (BAV) Registry
A clinical trial of Bicuspid Aortic Valve, sponsored by University of Michigan.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT01756222 is a study of Bicuspid Aortic Valve that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 5,000 participants, above the 1,600-participant average among 4 other Bicuspid Aortic Valve trials with a reported enrollment target (213% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01756222, a study of Bicuspid Aortic Valve, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this registry is to gather information on patients with bicuspid aortic valve disease.
Conditions Studied
Study Locations (1)
Michigan
- Univeristy of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2010-04 |
| Est. Completion | 2040-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756222
The ClinicalTrials.gov registry entry for NCT01756222 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,600-participant average among 4 other Bicuspid Aortic Valve trials with a reported enrollment target (213% higher). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bicuspid Aortic Valve appearing as the primary indexed condition, and to 0 interventions.
NCT01756222 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01756222 about?
NCT01756222 is a clinical study titled "Bicuspid Aortic Valve (BAV) Registry". The purpose of this registry is to gather information on patients with bicuspid aortic valve disease.
What is the current status of trial NCT01756222?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2010-04. Estimated completion is 2040-12.
What conditions does trial NCT01756222 study?
This clinical trial studies the following conditions: Bicuspid Aortic Valve.
Who is sponsoring clinical trial NCT01756222?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01756222 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bicuspid Aortic Valve
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry
RECRUITING
-
Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial
RECRUITING · NA
-
Identification of Genetic Causes of Bicuspid Aortic Valve Disease
ACTIVE NOT RECRUITING
-
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.